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1. Introduction 
The study of the metabolic fate of drugs is an essential and important part of the drug 
development process, research of drug metabolism pathways, drug-drug interactions, drug-
herb interactions, influence of genetic polymorphisms and other factors that influence the 
phase I and/or II metabolism of a drug. Different in vitro methods, from subcelullar to organ 
range, and in vivo studies are applied for the clarification of drug metabolism. The analysis 
of metabolites in complex biological matrices is a challenging task therefore several 
analytical methods for qualification and quantification of drug metabolites are used. Liquid 
chromatography coupled with mass spectrometry (LC-MS) has become the most powerful 
analytical tool for screening and identification of drug metabolites in biological matrices. 
However, adequate sample preparation is a key prerequisite aspect of successful 
quantitative and qualitative bioanalysis. Different approaches for metabolite quantification 
in biological samples from direct quantification, indirect quantification through parent drug 
after metabolite hydrolysis to quantification supported by using response factors between 
drug and their metabolites are often used. The most frequently used method for 
quantification is liquid chromatography coupled to different detectors such as mass 
spectrometer or UV detector. The LC-MS/MS methods are considered as most appropriate 
for determination of drugs and their metabolites and are also best suited for high 
throughput analysis. However, in LC-MS/MS assays, matrix effect and selection of suitable 
internal standards should be adequately addressed.  
2. Background of drug metabolism 
The study of the metabolic fate of drugs is an essential and important part of the drug 
development process. During drug evaluation the research of drug metabolism is of high 
importance especially when metabolites are pharmacologically active or toxic or when a 
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drug is extensively metabolized [1]. Interindividual differences in drug metabolism also 
lead to the research of factors that affect drug metabolism [2, 3]. Moreover, a metabolism of 
toxic substances is also frequently investigated [4]. 
In early discovery, drug metabolism input provides a basis for choosing chemical structures 
and lead compounds with desirable drug metabolism and pharmacokinetic (DMPK) or 
safety profiles [5, 6]. It is the fact that the shift of the rate of drug attrition from 40% in 1990 
to 10% in 2000 was due to increased efforts in applying DMPK principles for drug 
development. Beside traditional drug metabolism research that focuses on absorption, 
distribution, metabolism and excretion in vitro and in vivo studies, the knowledge about 
pharmacogenetics, pharmacogenomics and transporters brought many advances in drug 
metabolism research [5]. For the feasibility to successfully monitor the drug metabolism, 
suitable bioanalytical methods have to be developed and validated. Studies of metabolic fate 
of drugs in living systems may be divided into three areas: 1) elucidation of 
biotransformation pathways, 2) determination of pharmacokinetics of the parent drug 
and/or its primary metabolites and 3) identification of chemically-reactive metabolites that 
are important in drug-induced toxicity [7].  
Metabolism is a process of biotransformation when drugs are transformed into a different 
chemical form by enzymatic reactions. Mainly, metabolism increases drug hydrophilicity 
and decreases the toxicity and activity of most drugs. On the other hand, the 
biotransformation reactions could lead to bioactivation of drugs in which case the 
metabolite is more toxic and/or more active than the parent drug (reactive metabolite 
formation) [8]. The mechanism of bioactivation of drugs may be classified into following 
categories: biotransformation to stable but toxic metabolites, biotransformation to 
electrophiles, biotransformation to free radicals and formation of reactive oxygen 
metabolites. Additionally, bioactivations are also the transformations of a prodrug, 
promoiety or bioprecursor prodrug to a more effective metabolite [9]. Prodrug approach is 
commonly used in order to overcome the poor bioavailability of the active form of the drug. 
In case when prodrug consists of two pharmacologically active drugs that are coupled 
together in a single molecule it is called promoiety. Another type of prodrug is a 
bioprecursor drug which does not contain a carrier or promoiety, but results from a 
molecular modification of the active agent itself [9]. 
There are several factors influencing drug metabolism such as genetic, physiologic, 
pharmacodynamic and environmental factors. CYP2D6, CYP2C19, CYP2C9, CYP3A4, 
CYP3A5 are enzymes that are responsible for metabolism of many marketed drugs and are 
also highly polymorphic [10]. Many non-cytochrome P450 drug metabolizing enzymes also 
play important role in the metabolism of a variety of drugs. Among them polymorphisms of 
thiopurine methyltransferase (TPMT), butyrylcholinesterase, N-acetyltransferase (NAT) and 
UDP-glucuronosyltransferase (UGT) influence the metabolism of drugs [11]. Different 
physiological factors such as age, sex, disease state, pregnancy, exercise, circadian rhythm 
and starvation lead to the impaired metabolism among subjects and should be taken into 
consideration when evaluating the drug metabolism. Dose, frequency, route of 
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administration, tissue distribution and protein binding of the drug affect its metabolism. 
Moreover, environmental factors such as environmental chemicals, co-administered drugs, 
tobacco, smoking, alcohol drinking and dietary constituents may change not only the 
kinetics of enzyme reaction but also the whole pattern of metabolism, thereby altering the 
bioavailability, pharmacokinetics, pharmacologic activity or the toxicity of the drug [10, 11].  
3. Drug metabolic pathways  
Drugs are metabolized by different reactions that are classified into two groups: phase I 
and phase II. Phase I reactions include oxidation, reduction and hydrolysis. The function 
of phase I reactions is to introduce a new functional group within a molecule, to modify 
an existing functional group or to expose a functional group that is a substrate for phase II 
reactions. Phase I reactions are responsible for enhancement of drugs’ hydrophilicity and 
consequently facilitate the excretion. Phase II reactions represent conjugating reactions 
and mainly further increase the hydrophilicity and facilitate the excretion of metabolites 
from the body [10]. Enzymes that catalyze phase I reactions include microsomal 
monooxygenases (cytochrome P450, flavin-dependent monooxygenase) and peroxidases, 
cytosolic and mitochondrial oxidases, reductases and hydrolytic enzymes. Cytochrome 
P450 enzymes may catalyze aliphatic hydroxylation, N-, O-, S-dealkylation, oxidative 
dehalogenation, epoxidation [6]. The participation (%) of hepatic CYP450 isoforms in the 
metabolism of clinically important drugs is as follows: 3A4/5 (36%), 1A1 (3%), 1A2 (8%), 
2B6 (3%), 2C8/9 (17%), 2C18/19 (8%), 2D6 (21%), 2E1 (4%) [10]. Flavin-dependent 
monooxygenase, a flavoprotein, is a microsomal monooxygenase that is not dependent on 
cytochrome P450. It is capable of oxidizing nucleophilic nitrogen and sulfur atoms [6, 10]. 
Other typical phase I oxidation enzymes are monoamineoxidase (MAO), diamineoxidase 
(DAO), cyclooxygenase (COX), alcohol dehydrogenase (ADH), aldehyde dehydrogenase 
(ALDH), molybdenum hydroxylase (include aldehyde oxidase, xanthine oxidase and 
xanthine dehydrogenase). In addition to promoting oxidative metabolism, cytochrome 
P450 enzymes may also catalyze reductive biotransformation reactions for the reduction 
of azo and nitro compounds to primary amines [10, 12]. Hydrolytic enzymes that consist 
of non-specific esterases and amidases are also a member of phase I enzymes of 
metabolism [6, 10]. 
Phase I reactions may be followed by phase II reactions; however preceding phase I 
reactions are not a prerequisite. Phase II enzymes are highly capable of polarizing 
lipophilic drugs through conjugation with a polar substrate that facilitates excretion 
[13]. Contrary to phase I reactions, phase II reactions demand energy to drive the 
reaction. Energy is usually consumed to generate a cofactor or an activated intermediate 
then utilized as co-substrate [6]. Phase II reactions are catalysed by UDP-
glucuronosyltransferases (UGT), sulfotransferases (SULT), N-acetyltransferases (NAT), 
glutathione-S-transferases (GST) and methyltranserases [6, 10, 13]. Of the conjugating 
reactions glucuronidation, which catalyzes the transfer of glucuronic acid to aliphatic 
and aromatic compounds, is the most important. UGTs are able to form O-, N- and S-
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glucuronides and require uridine diphosphate glucuronic acid for glucuronide 
formation [6, 10].  SULT is the enzyme responsible for the formation of sulfate esters in 
the presence of co-substrate 3’-phospohoadenosine-5’-phosphosulfate (PAPS). Aromatic 
amines, hydrazines, sulfonamides and certain aliphatic amines are biotransformed to 
amides in a reaction catalyzed by N-acetyltransferase and utilize acetyl coencyme A as 
cofactor [6]. Another important conjugating reaction is a conjugation with glutathione 
which is present in many cells at high concentrations. Glutathione conjugation captures 
reactive electrophiles and transforms them to stable, often non-toxic tioethers [6]. 
Methylation is a process that results in a formation of O-, N- and S-methylated products 
by the transfer of methyl group from methionine [10]. 
4. Models for evaluation of drug metabolism  
In this chapter different in vitro and in vivo models for the evaluation of drug metabolism are 
presented. Advantages and disadvantages of subcellular fractions (microsomes, 
recombinant enzymes, cytosolic liver fractions, liver S9 fraction), cellular fractions (isolated 
hepatocytes, immortal cell lines, liver slices, perfused liver), in vivo animal and human 
studies will be presented.  
Biotransformation occurs in liver, intestine, kidney, lungs, brain, nasal epithelium and skin. 
Since liver is the most important organ for drug metabolism [14, 15] the liver-based in vitro 
technologies for evaluation of drug metabolism are presented below. In vitro models that 
range from whole cell system to enzyme preparations are now increasingly applied for 
quantitative and qualitative assessment in preclinical drug development, post-approval 
routine checks, identification of metabolic determinant factors and prediction of drug-drug, 
herb-drug and food-drug interactions [15].  
4.1. Recombinant human CYP and UGT enzymes (supersomes, baculosomes) 
Recombinant human CYP and UGT enzymes have proven to be a useful tool in in vitro 
biotransformation studies. This in vitro model, referred to also as supersomes or 
baculosomes, is produced by transfection of insect cells with cDNA for human CYP and 
UGT by baculo virus, namely insect cells lack endogenous CYP and UGT activity. The 
advantage of this system is that enzyme activity of one single CYP or UGT isoform is 
expressed and therefore the assessment of individual metabolic enzyme and its contribution 
to the metabolic pathway could be performed. Additionaly, this in vitro system could be 
used also for the evaluation of drug-drug interactions. Moreover, due to availability of 
supersomes with different CYP and UGT genotypes, the influence of different 
polymorphisms on drug biotransformation could be estimated. Currently, all common 
human CYPs and UGTs co-expressed with NADPH-cytochrome P450 reductase are 
commercially available. The disadvantage of this in vitro model is the latency of 
glucuronidation because the active site of UGT is shielded behind a hydrophobic barrier. To 
resolve this problem a pore-forming agents such as alamethicin are used [14-18]. 
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When performing the experiment with supersomes, the experiment with control 
nontransfected supersomes should be conducted. A NADPH regenerating system (NRS), 
which consists of β-NADPH, glucose-6-phosphate and glucose-6-phosphate dehydrogenase, 
or NADPH is required in the incubation for the evaluation of CYP activity and uridine 
diphospoglucuronic acid (UDPGA) has to be added as a cofactor when evaluating UGT 
enzyme activity [14-16].  
4.2. Human liver microsomes (HLM) 
HLM are vesicles of hepatocyte endoplasmic reticulum obtained by differential 
centrifugation of liver preparations (homogenates) from fresh human liver, liver slices, liver 
cell lines and primary hepatocytes. This subcellular fraction is a rich source of following 
enzymes: cytochrome P450s, flavin-monooxigenase (FMO), carboxyl esterases, epoxyde 
hydrolase and UGTs. Therefore, HLM are most frequently utilized in vitro model in drug 
metabolic profiling and drug interaction studies. Moreover, the influence of specific 
isoenzymes is studied using liver microsomes in the presence of specific inhibitors. There 
are interindividual variations in the activity of human liver microsomes; therefore they can 
be utilized also to study interindividual variability. In case of general estimation of drug 
metabolism, pooled microsomes from a large bank of individual liver tissues can be used to 
overcome the influence of interindividual variability. Microsomes from other human organs 
(intestine, kidney, lung) [19] are also available and are utilized to evaluate extrahepatic 
metabolism. Additionally, gender-specific microsomes are available for the estimation of 
gender-based discrepancies in drug biotransformation. In drug discovery process HLM are 
used for metabolite identification, evaluation of interspecies differences in drug metabolism, 
prediction of in vivo clearance, reaction phenotyping and metabolic pathway identification 
[14-18, 20]. 
NADPH or NRS is required in the incubation for the estimation of CYP activity. In order to 
evaluate the UGT activity UDPGA and alamethicin (pore-forming reagent) are required [14-
16]. 
The advantages of HLM are ease of use, low costs, best-characterized in vitro model for 
estimation of drug biotransformation, easy storage, appropriate for studying of 
interindividual and population-based variation, long term storage, provide qualitative 
estimations of in vitro drug metabolism, convenient tool for high throughput screening of 
compounds, appropriate for lead compound optimization studies and drug interaction 
studies. However, some disadvantages of HLM also exist. HLM are not appropriate for 
quantitative estimation of drug biotransformation because of absence of enzymes like 
NAT, GST and SULT and cofactors needed. This limits the expected metabolic 
competition and formation of some in vivo present metabolites. Another drawback is a 
very difficult assessment of the fraction of drug bound to plasma proteins versus to 
microsomes which is an important factor in the estimation of in vivo biotransformation 
[14-16, 18].  
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4.3. Cytosolic fraction 
Cytosolic fraction is an in vitro model that has not been used very often so far. Like HLM, 
cytosol is produced by differential centrifugation of liver homogenate. Soluble enzymes of 
phase II such as NAT, GST, SULT, carboxylesterase, soluble epoxide hydrolase, diamine 
oxidase, xanthine oxidase and alcohol dehydrogenase are expressed in cytosolic fraction, 
but only first three are expressed at higher concentration. This in vitro model requires 
cofactors like acetyl coA, dithiothreitol and acetyl coA-regenerating system for NAT, PAPS 
for SULT, glutathione for GST activity [14-16, 18].  
The main advantage is the presence of only aforementioned enzymes at higher 
concentrations than in liver S9 fraction. The biotransformation by NAT, GST or SULT can be 
studied separately or in combination depending on the cofactors added. The main 
disadvantage is the absence of UGT and therefore glucuronidation cannot be studied by this 
model [14-16, 18].  
4.4. S9 fractions 
S9 fraction contains both microsomal and cytosolic fractions and consequently expresses a 
wide range of metabolic enzymes – CYP, FMO, carboxylesterases, epoxide hydrolases, UGT, 
SULT, methyl transferases, acethyltransferases, GST and others. This in vitro model could be 
employed for metabolic, toxicity and mutagenicity studies. Similar to upper mentioned in 
vitro models the addition of cofactors is needed; NADPH or NRS for CYP, UDPGA for UGT, 
acetyl coA, dithiothreitol and acetyl coA-regenerating system for NAT, PAPS for SULT and 
glutathione for GST [14-16, 18, 20]. 
The main advantage over microsomes and cytosolic fraction is a more complete 
representation of the metabolic profile due to the presence of phase I and phase II enzymes. 
However, a disadvantage is the overall lower enzyme activity in the S9 fraction compared to 
microsomes and cytosol, which may leave some metabolites unnoticed [14-16, 18]. 
4.5. Cell lines 
This in vitro model is less popular than other described models due to dedifferentiated 
cellular characteristics and lack of complete expression of all families of metabolic enzymes. 
The sources of cell lines are primary tumors of liver parenchyma. Currently available cell 
lines are Hep G2, Hep 3B, SNU-398, SNU-449, SNU-182, SNU-475, BC2, PLC/PRE/5, C3A, 
SK-Hep-1 and among them Hep G2 cell line is most frequently used for biotransformation 
studies. The metabolic activity of liver cell lines is generally low compared to freshly 
isolated human hepatocytes. Metabolic activity of some metabolic enzymes is even not 
detected. The problem of low activity could be partly overcome by the pretreatment of cell 
lines by inducers of various metabolic enzymes. But still the induced activity is below the 
enzymatic activity in freshly isolated human hepatocytes. Liver cell lines require 
appropriate culture medium, whose composition significantly influences the metabolic 
activity. The described in vitro model is easy to culture and have stable enzyme 
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concentration. On the other hand, the absence or low expression of most important phase I 
and phase II drug metabolizing enzymes limits the application of this in vitro model. 
Moreover, metabolites are not easily detected and it is difficult to investigate individual 
enzymes due to their low expression level [14-16].  
4.6. Transgenic cell lines 
Transgenic cell line is a cell line that recombinantly expresses human phase I and/or phase II 
enzymes. All important human CYPs and UGTs have been expressed in this way to 
overcome the limitations of liver cell lines. Cell lines may be transfected at high efficiency 
using protoplast fusion. The main advantages are the ease of culturing, high expression of 
CYP and UGT isoenzymes, possibility to study single enzyme reactions and the influence of 
one isoenzyme or a combination of a number of isoenzymes. This in vitro model can also be 
used in the study of metabolite structures, pharmacological elucidation and to assess drug-
drug interactions. The main drawback is that only one or a few of isoenzymes are expressed, 
therefore the complete in vivo situation cannot be reflected. Moreover, transgenic cell lines 
are more expensive than other enzyme-based technologies [14-16, 18]. 
4.7. Hepatocytes 
Hepatocytes are well-established, well-characterized and frequently used in vitro model in 
drug biotransformation research. This in vitro model could be employed for the evaluation 
of metabolic stability, metabolite profiling and identification, drug efficacy, hepatic 
proliferation, hepatotoxicity and drug-drug interactions. Phase I and phase II drug 
metabolism pathways can be studied by the use of primary hepatocytes and cultured 
hepatocytes. Like with microsomes interindividual variation can be observed with 
hepatocytes. This can be overcome by using mixture of hepatocytes from different donors. 
Cryopreservation of hepatocytes offers many advances in the experimentation, namely 
activity of most phase I and phase II enzymes is retained.   
Primary hepatocytes are obtained by collagenase perfusion of whole liver or a part of liver. 
This in vitro system has strong resemblance of in vivo situation due to heterogeneity of 
enzyme expression in human liver and preservation of drug metabolizing enzymes at in vivo 
levels. Another advantage of primary hepatocytes is the ease of use and high throughput. 
The important disadvantage is the drop of hepatocytes viability during incubation period 
(viable 2-4 hrs). Moreover, lack of liver non-hepatocyte cells which may be necessary for 
cofactor supply, lack of cell polarity, cell-cell and cell-matrix contacts limits the in vivo 
resemblance [14-18, 20].  
After isolation, hepatocytes can be cultured in a monolayer in order to prolong the viability 
to 4 weeks. This characteristic in combination with the prolonged regulatory pathways 
allows the use of this in vitro model in studies of up-regulation or down-regulation of 
metabolic enzymes. However, cultured hepatocytes gradually lose viability and liver 
specific function. Many factors influence the morphology and functions of hepatocytes in 
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culture: medium formulation, extracellular matrix, initial cell suspension and density, drug 
concentrations. Hepatocytes could also be cultured in a sandwich configuration where 
hepatocytes are placed between two layers of gelled extracellular matrix. This type of 
culture retains liver hepatocyte specific functions for a longer period [18, 20]. 
4.8. Liver slices 
Liver slices and hepatocytes are the most physiologically relevant in vitro techniques used 
for quantitative and qualitative measurement of hepatic phase I and phase II metabolism of 
drugs due to full complement of enzymes and cofactors. High-precision tissue slicers (e.g. 
Krumideck slicer, Brenden-Vitron slicer) are used for the production of liver slices of 
uniform thickness (less than 250 µm). The advantage of liver slices over hepatocytes lies in 
the intact structure of liver tissue containing hepatic and non-hepatic cells, normal spatial 
arrangement and possibility of morphological studies. The described in vitro model allows 
higher throughput compared to isolated perfused liver. Another advantage is the non-
requirement for digestive enzymes and consequently the preservation of intact tissue 
structure. Moreover, no addition of cofactors is needed for enzyme activity. However, some 
disadvantages of this model are known: decrease of CYP activity in short time due to 
impaired diffusion of nutrients and oxygen in the liver slice, damaged cells on the outer 
sides of the slice, inadequate tissue penetration of the test medium, short viability period (5 
days), lack of optimal cryopreservation procedures and a need for expensive equipment [14-
16, 18, 20]. 
4.9. Isolated perfused liver 
Isolated perfused liver gives an excellent representation of the in vivo situation but it is not 
used frequently due to practical inconveniences. Normally animal liver tissue on a small 
scale is used, but never human liver tissue. The additional advantages of this in vitro model 
are also three-dimensional architecture, presence of hepatic and non-hepatic cell types, 
possibility to collect bile. The important disadvantages of this model are: poor 
reproducibility, functional integrity limited to 3 hours, difficult handling, poor perfusion of 
cells by nutrients and oxygen, low throughput and no availability of human liver. This 
model is useful only in case when bile secretion is the subject of research [14-16].  
4.10. Animal and human in vivo studies 
The identity of metabolites present in any matrix of animal or human provides essential 
information about the biotransformation pathways involved in the clearance of a drug. 
When the metabolite profiling of a parent drug is similar qualitatively and quantitatively 
between animal and human, we can assume that potential clinical risks of parent drug and 
metabolite have been adequately investigated during nonclinical studies. When a difference 
arises between in vitro and in vivo findings, the in vivo results should always take precedence 
over in vitro studies [21]. The FDA guidance encourages the identification of differences in 
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drug metabolism between animals and humans as early as possible during the drug 
development process in order to find unique human metabolites and major metabolites [1, 
21]. FDA defines that metabolites will need to undergo additional safety evaluation when 
steady-state systemic exposure to metabolite in humans exceeds 10% of parent drug 
exposure (disproportionate metabolite) [1].  
The results of aforementioned in vitro studies can be correlated to in vivo situation and vice 
versa. This multidisciplinary approach of translational medicine yields an insight into 
complex mechanisms of drug disposition. The principle of translational medicine is 
presented on raloxifene, a selective estrogen receptor modulator, which exhibits quite large 
and unexplained interindividual variability in pharmacokinetics and pharmacodynamics [2, 
3, 19, 22]. The gained knowledge about drug pharmacokinetics and pharmacodynamics 
insures a safer and more effective treatment strategy in the clinical setting. 
5. Qualitative evaluation of metabolites 
The known identity of metabolites is the prerequisite for a suitable metabolic assessment of 
drugs. Liquid chromatography coupled with mass spectrometry has become the most 
powerful analytical tool for screening and identification of drug metabolites in biological 
matrices. A short overview of analytical strategies for identification of metabolites will be 
provided. More information regarding metabolite identification can be found in following 
review articles [7, 23-27]. The selection of suitable LC-MS instrumentation is needed for 
qualitative evaluation of metabolites. Moreover, this issue is also important for quantitative 
evaluation of metabolites as discussed in section 8. Additionally, some examples for 
metabolite identification using LC-MS/MS will be provided in this section.    
5.1. LC-MS instrumentation 
5.1.1. Ionization techniques 
A LC-MS ion source has the double role of eliminating the solvent from the LC eluent and 
producing gas-phase ions from the analyte. The application of atmospheric pressure 
ionization (API) methods has provided a breakthrough for the LC-MS systems and has 
brought it to the forefront of analytical techniques. Some ion sources such as API operate at 
atmospheric pressure where others like electron impact (EI) or chemical ionization (CI) 
operate in vacuum. While soft API interfaces, in particular electrospray, produce molecular 
ions with minimal fragmentation, high energy sources like EI mostly generate fragment 
ions. API techniques are most widely used for metabolite detection, identification and 
quantification [7, 28] due to the ability to operate at atmospheric pressure, good 
compatibility with reversed phase chromatography and generation of intact molecule ions 
at very high sensitivity. All three API techniques: electrospay ionization (ESI), atmospheric 
pressure chemical ionization (APCI) and atmospheric pressure photoionization (APPI) are 
complementary.  
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• Electrospay ionization is by far the preferred method for metabolite identification 
and quantification. It is the most universal technique for introducing the molecules 
into the gas phase and it is most gentle and therefore likely to yield an intact 
molecular ions. ESI is ideally suited for polar, ionic and thermally labile compounds 
such as drug metabolites; in particular glucuronides and others phase II metabolites. 
This technique requires ionization of analytes within solution prior to introduction 
into ion source and thus works best for fairy basic or acidic compounds. Depending 
on the voltage polarity, nebulised droplets trapping the ionized analyte will be 
positively or negatively charged. The reduction in size caused by solvent evaporation 
accounts for the increase in charge density in the droplet leading to its explosion 
when repulsive forces between charges exceed the cohesive forces of the droplet. This 
process occurs repeatedly until gas phase ions are produced [29]. Ions in solution are 
emitted into gas phase without application of heat making ESI suitable for analysis of 
thermo labile compounds. Many parameters, such as analyte and solution 
characteristics: pKa, analyte concentration, other electrolytes in solution, dielectric 
constant of the solvent, affect the ion formation process [7]. The effects of several 
mobile phase additives on the ionization efficiency have been reviewed [30] and will 
be discussed later (section 8). Depending on the chemical structure of an analyte, 
multiple-charged molecular ions can be formed, which is optimal for the analysis of 
biological macromolecules (e.g. proteins). Despite the numerous benefits of ESI, it 
suffers from a shortcoming in that it is susceptible to ion suppression effects from 
high concentrations of buffer, salts and other endogenous compounds in matrix 
solutions [23]. 
• Atmospheric pressure chemical ionization is more suited for less polar compounds. 
Certain classes of compound such as heavily halogenated analoges and highly 
aromatic compounds will run readily on APCI while giving no or a weak response 
on ESI [7]. APCI like ESI produces ions based on the API strategy, but thought a 
completely different process. Here, the liquid eluent is sprayed into heated chamber 
[450-550°C) where the high temperature of a nebulizer gas flow causes the 
immediate evaporation of the solvent and the analyte. In addition to volatility at the 
applied temperature, thermal stability of the analyte is also a prerequisite for the 
successful application of APCI (e.g. glucuronides may break down and appear in the 
form of protonated aglycone [31]. Ionization of analytes takes place in gas phase 
where due to high flux of electrons from corona discharge needle, solvent molecules 
initially react with electrons and form ions that produce protonated solvent ions 
through secondary reactions. These protonated solvent ions then transfer a proton to 
form protonated analytes. For efficient ionization, the employed mobile phase 
should be volatile and also amenable to gas phase acid-base reactions. APCI 
technique is less prone to ion suppression and provides a wider dynamic detection 
range than ESI due to ionization that occurs mainly in gas phase. Also, typically 
higher flow rate is used with APCI [1-2 mL/min) then that in conventional ESI (0.1-
0.5 mL/min) [23].  
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• Atmospheric pressure photoionization is relatively new ionization method. This 
technique can be used for ionization of analytes that are not easily ionizable by ESI and 
APCI. APPI has similar application range as APCI but slightly extended toward 
nonpolar compounds [32]. The APPI ion source is very similar to APCI source, except 
the APCI corona discharge needle is replaced by photoionzation lamp. Depending on 
the analyte proton affinity relative to the composition of the mobile phase, either a 
radical molecular ion (typically for nonpolar compounds) or a protonated molecular ion 
(typically for polar compound) is obtained. APPI has a potencial in the analysis of drug 
metabolites but more research is needed to fully understand the important parameters 
and factors that affect the ionization efficiency [33].  
5.1.2. Mass analyzers 
The function of mass analyzer is the separation of ions formed in ionization source 
according to their different mass-to-charge (m/z) ratios. The quality of mass separation is 
characterized by the degree to which close m/z values can be separated in the mass 
analyzer. Mass analyzers are classified regarding resolution into low and high resolution 
instruments. The later ones are associated with another important parameter, mass 
accuracy, which allows determination of elemental formula of particular analyte. The 
selection of suitable analyzer is driven by the purpose of the analysis and the instrument 
performance but also depends on the instrument availability and cost effectiveness.  
• Triple quadrupole instruments (QQQ) are the most common mass spectrometers in 
analytical laboratories, having most often been acquired for their evident strengths in 
high sensitivity quantitative analysis of known analytes. These instruments have been 
often applied also for metabolite identification due to wide availability and excellent 
tandem mass (MS/MS) properties. In QQQ, the first quadrupole filters ions of interest, 
the second quadrupole also called collision cell fragments these ions and further the 
fragment ions are filtered by third quadrupole before reaching the mass detector. Such 
QQQ configuration allows performing different scans such as full scan, product ion 
scan, precursor ion scan (PI), constant neutral loss scan (CNL), single ion monitoring 
(SIM) and selected reaction monitoring (SRM) or multiple reaction monitoring (MRM). 
PI and CNL are particularly useful in metabolite identification since both scanning 
modes do not require previous knowledge about the molecular weight of metabolites. 
High sensitivity for quantitative purposes is retained only when working in MRM 
mode, however, the detection sensitivity decreases dramatically when wide mass range 
is analyzed in a scanning mode. This is one of the major disadvantages of using QQQ 
for the screening of drug metabolites.  
• Ion trap instruments (IT) are like QQQ relatively inexpensive and compatible with 
wide range of ionization interfaces. These analyzers utilize ion trap chamber where ions 
are trapped and then selectively ejected from the chamber. Additionally, the resonance 
excitation applied in the trap provides efficient dissociation of the precursor ions to 
product ions. IT provides more sensitivity for structural elucidation than QQQ due to 
 Chromatography – The Most Versatile Method of Chemical Analysis 90 
its better sensitivity in full scan mode and efficient dissociation of the precursor ions 
which allows multiple stages mass spectrometry (MSn). Recently, to address classical 
ion traps (called also 3D IT) shortcomings of insufficient ion storage efficiency, capacity 
and deterioration of the mass spectrum and dynamic response range, linear IT has been 
developed [25]. The detection sensitivity in linear IT is at least two orders of magnitude 
higher than that in 3D IT. Because of these advantages, linear IT will probably in near 
future totally replace old 3D IT [23]. 
• Triple quadrupole-linear ion traps (QTrap) combine sensitive QQQ technology with 
high capacity of linear IT incorporating high trapping efficiencies. In this instrument, 
the last quadrupole of QQQ is replaced with a linear ion trap, which operates as a mass 
resolving quadrupole or a linear ion trap. This provides clearly increased metabolite 
screening capabilities compared to traditional IT or QQQ. QTrap enables high 
sensitivity, wide range mass scanning and MSn together with QQQ capabilities, such as 
PI, CNL and very high sensitive MRM data acquisition. 
• Time of flight (TOF) analyzers are the most suitable high resolution mass 
spectrometers for fast and cost-efficient metabolite identification. TOF are relatively 
simple and capable of recording all formed ions on a microsecond time scale offering 
high sensitivity detection. Ions are accelerated from the ion interface to a fixed kinetic 
energy and then pass through a field-free tube to the detector. The time needed for ion 
to reach the detector is proportional to its m/z ratio. TOF strength lies in its very high 
detection sensitivity when acquiring wide range data, enabling the simultaneous 
detection of data for all metabolites of interest in one run. High mass resolution and 
mass accuracy (< 3-5ppm) enable reliable and accurate identification of metabolites by 
determination of elemental formula of a metabolite. Additionally, the very high 
acquisition speed makes them ideal for fast chromatography [24].  
• Triple quadrupole-time of flight (Q-TOF) instruments combine first mass filter and 
collision cell of QQQ with TOF as the second mass analyzer. These instruments can 
operate as true tandem MS while providing accurate mass of the product ions. Most 
modern Q-TOFs have good linear response and are therefore also suitable for 
quantitative purposes. However, TOF instruments have not the ability to perform 
positive/negative switching in one run [24].  
• Orbitrap is another high resolution analyzer which is a hybrid composed of a linear IT 
and Fourier transform mass spectrometer. It is an effective alternative to the TOF 
instruments used for metabolite profiling. Orbitrap is capable of high sensitivity 
screening over wide mass range, MSn and tandem mass spectrometry with accurate 
mass data for both parent and fragment ion. However, it is not suitable for fast 
chromatography because it suffers from a slow data acquisition [24].     
• Fourier transform-ion cyclotron resonance (FT-ICR) is the third high resolution mass 
analyzer. The high sensitivity, accurate mass measurements, high mass resolution and 
MS/MS capabilities of FT-ICR make it attractive for structural determination of ions. 
However, the combined requirement of ultra-high vacuum system, superconducting 
magnets as well as sophisticated data system place the cost of these instruments beyond 
the means of most laboratories involved in drug metabolism studies [7]. 
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5.2. Strategies for metabolite identification 
MS methodology is the most suitable approach for metabolite identification as commonly 
low concentrations of drug metabolites are present in complex biological matrices. 
Appropriate LC-MS instrumentation is clearly critical to both, detection and structural 
elucidation, although alternative non-MS approaches may also be important in cases when 
MS data alone are not sufficient. Tandem mass spectrometry instruments are beside their 
key role for metabolite quantification also well suited for qualitative purposes. Tandem 
mass spectrometry experiments, which allow different scan mode possibilities, are by far 
most informational techniques for structural characterization of metabolites [23]. But these 
experiments require a set of injections to perform full scan and other scan analyses to 
identify metabolites of interest. The drive to more versatile and powerful instruments which 
can perform intelligent data dependent experiments has led to newer mass analyzers, such 
as high resolution Q-TOF instruments, which now dominate the metabolite identification 
field. 
5.2.1. Full scan 
The non-selective nature of full mass scan acquisition enables detection of practically all 
ionizable metabolites and giving most complete information in terms of metabolite 
molecular mass. However, two major disadvantages arise by this approach. Firstly, 
detection sensitivity using QQQ decreases dramatically when wide mass range is scanned. 
This obstacle can be overcome by using IT analyzers as its full scan is much more sensitive 
or even better by using TOF instruments which additionally enable accurate mass 
determination [23]. In case when only QQQ is available, a practical approach may be 
applied to improve sensitivity; the whole mass range should be divided to narrow scanning 
ranges by performing multiple analyses of the same sample. Secondly, other non-metabolite 
matrix compound may interfere with obtained MS data. A common procedure for 
metabolite detection involves analysis of test and control samples what then allows 
subtraction of control sample data. This approach is less successful when complex biological 
samples, such as plasma and urine, are examined. Expected metabolites in studied samples 
may be predicted based on biotransformation pathways of parent drugs what enables 
focused search of these compounds. The most common changes in mass caused by 
biotransformation are shown in Table 1.   
5.2.2. Precursor ion and constant neutral loss scan 
PI and CNL are more specific approaches for identification of unknown metabolites. This 
scan mode is only possible for tandem mass spectrometers and therefore suffers at 
sensitivity like other QQQ scanning acquisitions. In PI scan mode, the second quadrupole 
mass filter is set to pass only the selected product ions, while the first quadrupole mass filter 
scans a range of m/z values. In CNL scan mode, both quadrupoles are scanning m/z values 
while the m/z difference between the quadrupoles is kept constant. Several phase II 
metabolites at fragmentation lose a distinct neutral group that can be used for specific 
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identification of these conjugates. Glucuronides, sulfates and glutathione conjugates are 
often detected by CNL of m/z 176, 80 and 129, respectively. Typical PI for some drug 
conjugates in negative ionization mode like aliphatic sulfates, sulfonates and phosphates are 
m/z 97, 81 and 79, respectively [28]. Although PI and CNL provide high selectivity for 
identification of metabolites, the methods are based on predicted fragmentation behavior of 
metabolites what depends to some extent also on abilities of the analyst. Therefore, 
metabolites with unexpected fragmentation can be missed. Nevertheless, in combination 
with full scan data, PI and CNL is a powerful tool for metabolite identification. 
 
Biotransformation Change in molecular formula Change in mass (Da) 
Dehydration - H2O -18 
Demethylation - CH2 -14 
Dehydrogenation - H2 -2 
Hydrogenation + H2 +2 
Methylation + CH2 +14 
Hydroxylation + O +16 
Epoxidation + O +16 
S/N-oxidation + O +16 
Hydration + H2O +18 
Dihydroxylation + O2 +32 
Acetylation +C2H2O +42 
Sulfation +SO3 +80 
Glucuronidation +C6H8O6 +176 
Glutathione conjugation +C10H15O6N3S +305 
Table 1. The nominal mass changes in biotransformation of drugs by common metabolic reactions [28, 34] 
5.2.3. Product ion scan 
Product ion scan is used for structural characterization of the detected metabolites. In product 
ion mode, a precursor ion (metabolite) is selected in first quadrupole, fragmented in collision 
cell and the product ions are then scanned in second quadrupole. Structural information is 
obtained by interpretation of the fragmentation patterns for both metabolite and parent drug. 
Complete structural characterization of metabolites may be hindered by the absence of useful 
product ions in tandem mass spectrometry. To obtain more specific structural data, the use of 
multistage (MSn) scan by using ion trap instruments can be provided. The selected product ion 
can be selectively isolated and further fragmented, narrowing the potential sites of 
modification and providing a more complete assessment of the metabolite structure. 
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5.2.4. Multiple reaction monitoring  
Although the use of PI and CNL data acquisition improves the selectivity of metabolite 
detection when comparing with full scan acquisition, all three approaches have reduced 
sensitivity. For this reason, specific MRM screening may serve as alternative approach for 
metabolite detection. MRM is the most appropriate acquisition method for quantification of 
analytes. In this mode, the first quadrupole is set to pass only the selected precursor ion that 
is fragmented in collision cell and usually the most abundant fragment (product ion) is then 
filtered in a second quadrupole. Monitoring of specific transition for each analyte yields a 
superior signal-to-noise ratio with significantly higher selectivity. Utilizing metabolism 
prediction and knowledge of the tandem mass fragmentation of the parent drug, the 
approach gives a significant increase in sensitivity and enables a wide range of potential 
MRM transitions to be targeted. Although the possibility to overlook metabolites remains 
the targeting MRM is a powerful alternative for metabolite detection when sensitivity is an 
issue. Single ion monitoring is is another option to overcome low sensitivity of QQQ 
screening techniques. SIM is less specific and sensitive acquisition compared to MRM but 
may provide advantages when the potential metabolite fragmentation pattern cannot be 
predicted correctly. In this case a multiple SIM transitions of the predicted metabolites are 
performed, which are set accordingly to the expected nominal mass changes regarding to 
parent drug (Table 1). 
5.2.5. High resolution mass spectrometry 
The most widespread analyzer providing high mass accuracy (TOF, Orbitrap, FT-ICR) used 
in metabolite identification is TOF instrument. The specificity in the detection of metabolites 
with high resolution is significantly higher than that with unit resolution QQQ or IT 
instruments where the ion chromatograms can be recorded using a 0.1 mass unit window. 
The high selectivity provides also better sensitivity for the detection of metabolites. It was 
reported that detection limits for several drugs were 5-25 times better with accurate mass 
TOF, than with nominal mass TOF (same unit level than at QQQ) [28]. Accurate mass 
measurements enable to determine the elemental formula of metabolites. Moreover, exact 
mass shift enables the establishment of the change in molecular formula of the parent drug. 
For example, metabolites formed by hydroxylation and dehydrogenation (at same time) are, 
in this way separated from those formed via methylation, in spite that both reaction increase 
the molecular weight by 14 (Table 1) [24]. The benefit of reliable accurate mass 
measurements for structural elucidation of unknown metabolites is therefore extremely 
high. However, metabolites with the same exact mass cannot be distinguished by analyzers. 
In this case other approaches are needed. Ion mobility time-of-flight mass spectrometry (IM-
MS), which separates ions on the basis of their m/z ratios as well as their interactions with a 
buffer gas, is very convenient. The main advantage of IM-MS is the potential for separation 
of metabolite isomers without chromatographic separation which makes it a powerful 
analytical tool for investigation of complex samples [35]. 
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Q-TOFs are the key high resolution instruments for drug metabolism research. Q-TOF 
instruments provide sufficient mass resolution (up to 40,000) and accurate mass 
measurements (below 1 ppm). In addition, they can operate at relatively high scanning 
rates, which are considered as the main drawback of most of the Orbitrap based 
instruments. On the other hand, Orbitrap analyzers provide a resolving power of up to 
100,000 with mass accuracy below 1 ppm. FT-ICR analyzers provide ultrahigh mass 
resolving power greater than 200,000 but high purchasing and maintenance cost are beyond 
financial capabilities of most routine laboratories [27].  
5.2.6. Other approaches 
Other approaches can be applied to provide specific structural information in cases when 
MS data are not sufficient to determine metabolite structure. Hydrogen/deuterium exchange 
LC-MS allows studying mechanisms of MS fragment ion formation and metabolic pathways 
of drugs, as well as differentiate the structures of isomeric metabolites [7]. Metabolites can 
be isolated and purified from the incubations, followed by structural analysis by NMR. 
Alternatively, LC-NMR analysis can be performed on biological samples with minimal 
sample processing but certain limitations occur with this technique, such as lower sensitivity 
compared with LC-MS and the requirements of relatively expensive deuterated buffers in 
mobile phase. More recently, LC-NMR has been coupled with MS which enables 
simultaneous metabolite structure elucidation [25]. Tentatively identified structure of 
metabolites may also be synthesized and LC-MS data for these compounds are compared 
with data from the actual metabolites. 
5.3. Examples of metabolite identification 
Tandem mass spectrometry is well suited for identification of phase II metabolites [36]. As 
example for this approach, the elucidation of three raloxifene glucuronides in urine as well as 
their identity confirmation after bioproduction by using QQQ is provided [37]. 
Chromatograms of each bioproduced glucuronide standard obtained in ESI positive full scan 
mode gave only one chromatographic peak where MS spectra of each peak showed strong 
molecular ions at m/z 650, 650 and 826 for two raloxifene monoglucuronides and 
diglucuronide, respectively. Nominal mass shift of 176, 176 and 2 x 176 Da compared to parent 
drug (m/z 474) is characteristic for the structure of monoglucuronide and diglucuronide 
metabolites (Table 1). Product ion scan showed the same mass spectra for both predicted 
monoglucuronides: fragmentation of the parent ion m/z 650 to 474 and 112. Product ion spectra 
confirmed also diglucuronide structure by two subsequent m/z 176 neutral losses from the 
parent molecular ion (m/z 826), giving fragments of monoglucuronide (m/z 650) and of parent 
raloxifene (m/z 474) as well as additional m/z 112 fragment of raloxifene (N-ethyl-piperidine). 
Additionally, constant neutral loss scan (m/z 176) and precursor ion scans (m/z 112 and 474) in 
urine sample have been performed. The analysis in all three cases gave three distinct peaks in 
chromatograms at retention times for the diglucuronide, and both monoglucuronides (data not 
shown, but same retention times as in Figure 1) confirming again the structure of metabolites. 
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Another important point had to be considered, good chromatography was needed in order to 
separate both monoglucuronides since they cannot be distinguished based on MS. 
Representative LC-MS/MS chromatogram, using MRM acquisitions for quantitative purposes 
of raloxifene and its three metabolites in urine sample is shown in Figure 1.  
Identification of bisphenol A glucuronide and deuterated bisphenol A glucuronide in 
microsomal incubations [4] is another example. Twin peaks of metabolites with known mass 
difference [14] (Da in this case) are helpful for studying fragmentation paths. Product ion 
scan in ESI negative ionization mode for bisphenol A glucuronide (m/z 403) showed 
fragments m/z 227 (bisphenol A), 212 (bisphenol A fragment - loss of CH3) and 113. The 
molecular ion of deuterated bisphenol A glucuronide fragments from m/z 417 to m/z 241 
(deuterated bisphenol A), 223 (fragment - additional loss of CD3) and 113. Fragment m/z 
113, which is present in both cases represent a glucuronic acid fragment in negative 
ionization with subsequent loss of H2O and CO2. 
In case of reactive metabolite studies there are typical approaches to identify glutathione 
conjugates: increased mass shift 305 Da according to the parent, constant neutral loss of 
pyroglutamic acid (m/z 129) in the positive ionization mode and/or precursor ion of m/z 272 
in the negative ionization mode [34, 38]. Recently, an in vitro bioactivation study using these 
identification approaches has confirmed that bazedoxifene does not show the formation of 
glutathione conjugates compared to raloxifene what offers an improved safety profile of this 
third generation drug relative to other available SERMs [39]. 
The glucuronide metabolites may be also simply verified by using ß-glucuronidase which 
provides the conversion of the glucuronide to its aglycone (see next section). If the 
conversion is complete, this approach is valid for determination of the metabolite stock 
solution concentrations when small amounts of glucuronide standards are obtained or 
available [37].  
However, for more demanding application QQQ is usually not satisfactory. Identification of 
phase I and phase II metabolites of two antineoplastic agents was demonstrated by use of Q-
TOF [40]. In this study, 32 metabolites for dimefluron and 28 metabolites for benfluron were 
detected in the rat urine within 25 min chromatographic run. The identification of 
individual biotransformation was performed using high mass accuracy measurements for 
both full scan and tandem mass spectra by extracted ion chromatograms for expected 
masses of metabolites together with the information about characteristic neutral loss. 
Another study compared QQQ, linear IT (QTrap), TOF and Orbitrap instruments for 
identification of microsomal metabolites of verapamil and amitriptyline [41]. Only TOF 
found all 28 amitriptyline and 69 verapamil metabolites; both expected and unexpected. The 
TOF offered sensitivity and high mass resolution and also lowest overall time consumption 
together with the Orbitrap. Orbitrap also showed good mass resolution but was less 
sensitive, resulting in some metabolites not being observed. Approaches with QQQ and Q-
Trap provided the highest amount of fragment ion data for structural elucidation, but being 
unable to produce very high important accurate mass data, they suffered from many false 
negatives and especially with the QQQ from very high overall time consumption. 
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6. Approaches for metabolite quantification 
The demand for analyses of low-level drugs in complex biological samples has increased 
significantly in last years. New pharmaceuticals have typically high potency, so small 
doses are given and therefore the detection limits of these drugs and their metabolites are 
of great importance. Selective and sensitive analytical methods for the quantitative 
evaluation of these analytes are critical for the successful conduction of pharmacological 
studies. Metabolite quantification is always required when the metabolite is toxic or 
pharmacologically active or when the concentration of metabolite reaches or exceeds the 
parent drug concentration in plasma. Different approaches for metabolite determination 
in biological samples have been used which can be generally divided to direct 
quantification, indirect quantification through parent drug after metabolite hydrolysis or 
quantification supported by using response factors between drug and their metabolites. 
The key role in the selection of the particular approach is driven by the availability of 
suitable authentic standards. Hence some examples of metabolites production will be also 
shown here.  
6.1. Direct quantification  
Direct quantification is the most appropriate approach for metabolite determination in 
biological matrices but two major points need to be considered. Firstly, in general 
metabolites are much more hydrophilic than parent drug, especially glucuronides [34]. 
That fact has represented a hindrance for direct metabolite determination because 
chromatographic separation between these polar analytes and interfering matrix 
components could not be achieved in many cases. However, this problem has been 
overcome by advent of powerful liquid chromatography-tandem mass spectrometry 
instruments which allow direct quantification of these metabolites [42]. LC-MS/MS 
nowadays play predominant role in bioassays for pharmacokinetic and metabolism 
studies due to its inherent specificity, sensitivity and speed. Secondly, appropriate 
authentic standards are needed for reliable and accurate quantification in biological 
samples. Proper validation of analytical methods includes preparation of calibration and 
control samples in given biological matrices using suitable reference standards. Authentic 
metabolite standards are often not commercially available, particularly in the case of new 
drugs or drugs of abuse. Moreover, available metabolites may be very expensive and 
therefore not accessible for every research group, especially not in academic sphere. 
Furthermore, stable isotope labeled standards of metabolites, which are most convenient 
internal standards for LC-MS/MS analyses, are even less available and/or more expensive 
than unlabeled metabolites.  
In such situation question may arise why not quantitate metabolites concentration based on 
parent drug calibration curve as this standard are freely accessible. Modified structure of 
metabolites may change the response to quite diverse extent among various liquid 
chromatography detection systems. Mass spectrometry using atmospheric pressure 
ionization sources is very prone to this issue as the intensity of the MS signal strongly 
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depends on the analyte even at small structural changes. It has been reported that the 
response in ESI-MS differed by factor 25 for two oxidative isomeric metabolites with same 
chemical formula [43] or that no signal in contrary to parent drug has been observed for 
metabolite in positive ionization ESI. Detection of metabolite was in this case possible only 
in negative ionization mode [26]. However, with the commonly and easily used UV 
detection, the metabolites have often the same chromophore as the parent drug (but not 
always [40], hence giving similar response. But the main limitation of this technique in 
pharmacokinetic studies lies in not sufficient sensitivity and also in lower selectivity as some 
compounds does not have UV absorption at a wavelength to distinct it from the 
background. In contrast to UV, fluorescence and electrochemical detection can be very 
selective and sensitive. For electrochemical detection the response may also be very 
dependent on structure, especially for phase I metabolites which usually possess changed 
oxido-reductive properties compared to parent drug [34]. Beside that both detector systems 
are very specific what makes them of limited applicability.  
Direct quantification can also be performed without suitable standards. For that purpose 
detectors need to give an equimolar response for all compounds of interest. Additionally, 
such detectors should be highly sensitive with wide dynamic range, robust and easy to use, 
compatible with reverse-phase gradient elution and not prone to matrix interferences, 
namely give a response independent of compound [44]. Although there are sophisticated 
detectors available, few are used routinely for metabolite quantification. Beside radioactivity 
detector (RAD) which also require suitable standards (radiolabeled compounds) other 
compound response independent detectors has been recently discussed elsewhere [25, 44-
46]. Such approach has become even more important for metabolite evaluation in the light 
of recently introduced FDA guidelines on metabolites in safety testing, which recommends 
that all metabolites greater than 10 percent of parent drug should be examined [1]. Some 
further examples of metabolite quantification using accelerator MS [47], inductively coupled 
plasma MS [43], chemiluminescene nitrogen detector [48], quantitative NMR [49] and 
evaporative light-scattering detector [50] are given.  
6.2. Quantification using response factor 
Prerequisite to make this approach successful is the chromatographic separation of drug 
and all metabolites. Quantification is based on using LC-MS/MS in combination with 
detector that gives an equimolar response independent of the compound, usually with RAD. 
Response ratio of the metabolite to parent drug on RAD is then correlated to response ratio 
on LC-MS/MS. Low amounts of metabolites and parent drug in samples are measured by 
sufficiently sensitive LC-MS/MS, where the analysis of higher amounts allows detection on 
RAD and due to response factor enables calculating of metabolite concentration. The best 
way to perform analyses is to combine RAD with MS after liquid chromatography with 
splitting flow in order to obtain peaks of the metabolites and parent at the same retention 
times on both detectors [51]. RAD is convenient for such analyses because of the large 
dynamic range but its use is limited by the availability of radiolabeled standards. However, 
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the most straightforward detection technique generally found with LC-MS/MS is UV 
detection. Metabolites can be (semi)quantified using UV response ratio in cases when the 
parent drug chromophore offers sufficient selectivity, is not altered by metabolism and the 
metabolites are well separated from other drug related entities and endogenous compounds 
[46].  
This approach may be also reasonable to quantify metabolites in case of limited amounts of 
authentic standards. After determination of the response factors, metabolites could be then 
quantified based on calibration curve of parent drug [19]. A constant response factor is 
absolutely essential and therefore in such cases response factors should be periodically 
verified. Using the same instrument and without major instrument breakdowns, the 
response factor seems to be very stable over long periods [52]. 
6.3. Indirect quantification 
Refer to evaluation of glucuronides and other phase II metabolites. These metabolites are 
determined by cleavage of conjugates to yield the parent drug, which is subsequently 
detected. This indirect approach has several limitations, including the risk of incomplete 
hydrolysis, moderate repeatability and time consuming sample preparation [42]. Another 
drawback is non-selectivity of this procedure toward study of particular metabolite of 
interest when distinct drug metabolite conjugates are present in sample, like in case of 
morphine which is transformed to two isomeric metabolites. Morphine-3-glucuronide is an 
inactive metabolite but morphine-6-glucuronide possesses even greater pharmacological 
activity than the parent drug [53]. In such cases this approach is not suitable in 
pharmacokinetic studies as the overall drug concentration including more metabolites is 
determined in examined biological fluid. However, in the field of toxicology, doping control 
or drugs of abuse this information may be even more valuable [54, 55]. Nevertheless, direct 
quantification of metabolites and their indirect quantification via parent drug after 
metabolite hydrolysis may give comparable results like in case of buprenorphine 
metabolites [56]. 
Cleavage of conjugates can be performed by fast chemical hydrolysis or by gentle but time 
consuming enzyme hydrolysis. Deconjugation by ß-glucuronidase is the predominantly 
used approach. Different types of enzymes are commercially available but the most 
frequently used are ß-glucuronidases from E. coli or Helix pomatia, sometimes combined with 
arylsulfatase. ß-glucuronidase from Helix pomatia provides the advantage of the cleavage of 
glucuronide and sulfatate conjugates at same time what is important in the field of 
toxicology [6]. However, the glucuronidase activity is not as high as at E. coli. In order to 
achieve a successful enzyme hydrolysis it is crucial to pay attention on several factors, such 
as temperature, pH, enzyme origin, enzyme concentration and incubation time [57]. 
However, cleavage with ß-glucuronidase is not always preferential as for acyl glucuronides 
(ester conjugates) where alkaline hydrolysis is more suitable [55]. Acid hydrolysis may also 
be sometimes the better possibility for other glucuronide types [58]. N-glucuronides 
(primary, secondary and N-hydroxylated amines) are hydrolyzed under mild acidic 
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conditions but quartenary ammonium glucuronides under basic conditions [25]. 
Additionally, enzymatic hydrolysis of acyl glucuronides may be hindered due to acyl 
migration what leads to ß-glucuronidase resistant derivates [59]. Nevertheless, if the ß-
glucuronidase treatment is successful for the metabolite of interest, this procedure should be 
the method of choice.   
Another aspect for quantification using this approach has been shown recently [60]. 
Different benzodiazepines were determined via their metabolites by using acid hydrolysis 
of urine samples. The parent drug and all metabolites, conjugated as well as non-conjugated 
(I phase metabolites), were converted to corresponding benzophenone under studied 
conditions. Such approach reduces the specificity but at same time the overall sensitivity of 
the method increases, which makes such method suitable for drug abuse monitoring. 
6.4. Metabolite production 
Alternative approach for direct quantification is to obtain authentic metabolite standards. 
The chemical synthesis is mainly suitable for achieving phase I metabolites, like O-
demetylation, N-demetylation, N-oxidation, carbonyl reduction and other. However, 
synthesis of the phase II metabolites can be cumbersome and stereochemically demanding 
and hence go beyond possibilities of most laboratories [34]. Versatile alternative to chemical 
synthesis is enzyme-assisted in vitro production of these metabolites using liver 
homogenates, liver microscale cultures, cell culture lines or microbial systems where each of 
these methods has its specific drawbacks [61, 62]. Raloxifene, which is metabolized to two 
distinct monoglucuronides and one diglucuronide, is an illustrative example for in-house 
production of authentic standards. Glucuronide yield by chemical synthesis was very low 
and not sufficient enough to characterize those metabolites. On contrary, the biosynthesis 
with recombinant human UGT enzymes turned out to be successful in converting parent 
drug to both monoglucuronides [63]. In last attempt the bioproduction of all three 
metabolites could be accomplished by using the microorganism Streptomyces sp [37]. For 
more detail about raloxifene in vitro metabolism refer to [19]. Availability of both metabolite 
standards – unlabeled and stable isotope-labeled internal standards is even more important 
for reliable quantification using LC-MS/MS. Stable isotope labeled metabolites can be 
obtained by microsomal incubation of labeled drug, of course if it is available and not too 
expensive [4]. The alternative approach is to use a labeled UDP-glucuronic acid as cofactor 
in bioproduction of metabolites [62].  
Moreover, metabolites can be isolated from urine after oral administration and after 
purification and characterization they can be used as standards. Bisphenol A glucuronide 
and its deuterated glucuronide were isolated from rat urine [64]. Recently published work 
dealing with microsomal bioproduction of the same metabolites [4] revealed some 
drawbacks of the isolation approach. Beside ethical considerations, the yield of both 
standards was much lower from animal samples (microgram scale) than microsomal 
incubates (milligram scale). Additionally, urine as matrix requires also more extensive 
purification procedure in order to obtain highly pure standards. However, in cases where 
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metabolites cannot be produced by proposed in vitro models the in vivo biological samples 
are then the only media for isolation of those metabolites. 
7. Sample preparation 
Adequate sample preparation is a key aspect of quantitative bioanalysis and it is usually the 
most time consuming part of analyses. Interfering matrix compounds, such as proteins, 
lipids, salts, other endogenous and background compounds, should be removed in sample 
pretreatment, not only to avoid column clogging and instrument soiling, but also to improve 
the sensitivity, selectivity and reliability of analyses. Selection of an appropriate preparation 
procedure depends upon metabolite characteristics, their expected concentrations, the 
sample size and matrix, and the availability of analytical techniques for analyte 
quantification. Insufficiently treated samples may cause interfering peaks when using 
spectroscopic detection techniques such as UV-absorbance or fluorescence. However, 
analyses by LC-MS/MS are less prone to sample matrix and therefore usually require less 
pretentious sample clean up. Commonly and widely applied sample preparation techniques 
include protein precipitation (PP), liquid-liquid extraction (LLE) and solid-phase extraction 
(SPE). Manual operations associated with sample treatment may be very labor intensive and 
time consuming and that could be avoided with automation in 96-well plate format or direct 
sample injection followed by on-line extraction methods.  
7.1. Protein precipitation 
Protein precipitation (PP) is simple and straightforward method widely used in bioanalysis 
of plasma samples. It is accomplished by using organic solvent (typically acetonitrile or 
methanol) or an acid (typically perchloric or trichloroacetic acid). It is followed by 
centrifugation to separate proteins from liquid supernatant and additionally, supernatant is 
sometimes diluted with chromatographically compatible solvent (e.g. mobile phase eluent). 
Supernatant can be directly injected or pre-concentrated after evaporation and 
reconstitution. Although only proteins are removed, other endogenous compounds remain 
which can still cause interferences such as matrix effect in mass spectrometry analyses. PP 
offers a generic and fast sample preparation technique that can be easily automated. The 
method has been also extended to quantification of drugs and metabolites from whole blood 
[65]. The same sample preparation technique in not suitable only for plasma but can be 
transferred to other biological samples such as urine. Moreover, the absence of proteins in 
these matrices allows direct injection without sample pretreatment. Nevertheless, it is 
advisable to dilute and filter or centrifuge the samples to reduce matrix effect and to remove 
eventually present particles [42]. Many examples for metabolite determination using PP, 
mainly in serum and urine, can be found in recently published review articles [66-68]. PP is 
also the most convenient method for less complex biological matrices in pharmacokinetic 
studies, such as hepatocytes [69] or microsomes [4]. In this case protein precipitation by ice-
cold methanol (triple volume) at the same time terminates the incubation reaction and 
introduces internal standard to the final sample. 
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7.2. Liquid-liquid extraction 
To obtain a sensitive analysis for a complex biological media (plasma, urine) liquid-liquid 
extraction (LLE) or solid phase extraction (SPE) are often required instead of PP. LLE 
sometimes gives better sample clean up showing less matrix effect in comparison with 
SPE [70]. Additionally, LLE is in general simpler and may be applicable to almost all 
laboratories using large variety of available solvents. LLE is also less expensive and 
flexible as several samples may be prepared in parallels. On the other hand emulsion 
formation, mutual solubility of analytes in both phases or large volumes of flammable 
and/or toxic solvents should be considered. In recently published comprehensive 
overview of methods for measurement of antidepressants and their metabolites in 
biofluids, many examples of extraction including LLE conditions can be found [67]. 
Offline methodologies are often very tedious and time consuming, and the risk of sample 
loss and/or contamination is high. Lack of automation possibilities is therefore another 
important LLE drawback. However, several research groups have developed different 
approaches to solve mixing and phase separation problems typically seen in a 96-well 
plate LLE method [71]. A semi automated LLE procedure using 96-well plates was 
reported [72].  
7.3. Solid-phase extraction 
SPE has become very popular and is nowadays considered as a basic technique in many 
laboratories for sample preparation of drugs and their metabolites from biological 
matrices. SPE offers several advantages over LLE, including higher recoveries, no 
problems with emulsions, less solvent consumption and a smaller sample volume 
requirement. Moreover, automation of sample treatment with high speed and feasibility 
for treatment of numerous samples at one time is possible. However, a drawback often 
associated with SPE is their high dead volume, which can lead to loss of sample and may 
cause dilution of applied samples. SPE column lot production variability or column 
blockage due to sample viscosity or precipitation may also occur. Columns can be 
supplied as individual units for manual use and also in 96-well plate format for use with 
robotic sample processors. The column dead volume has been overcome with a novel 96-
well SPE plate that was designed to minimize elution volume (< 25µL). The evaporation 
and reconstitution step that is usually required in SPE is avoided due the concentration 
ability of the sorbent [71].  
SPE is based on chromatographic separation such as liquid chromatography. Wide 
variety of cartridge types and solvents make SPE procedure suitable for many polar or 
nonpolar analytes. The extraction procedure can be a generic protocol or can be 
optimized if better sample clean up is desired. Beside classical reverse phase (e.g. C8 or 
C18) also polymer reverse phase (e.g. divinylbenzene, N-vinylbenzene), polymer ion-
exchange (e.g. weak or strong anion/cation-exchange) or mixed mode ion-exchange 
sorbents are available. Polymeric reverse phase materials possess both hydrophilic and 
lipophilic properties and are capable of capturing polar analytes such as drug 
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metabolites [66]. Another advantage regarding silica based phase is ease of use, since 
there is no need to keep those phases moistened to maintain interaction. Mix mode ion-
exchange and ion-exchange sorbents are even more convenient since strongly retained 
ionic metabolites allow rigorous washing of cartridge (e.g. 100% methanol) achieving 
cleaner sample with less matrix interferences [73].  
There are now commercially available protein precipitation devices in plate format that 
allow PP within the plate whilst also removing phospholipids (HybridSPETM and Waters 
OstroTM). This novel semi automated sample clean up procedure includes combination of PP 
and SPE. Proteins in sample are firstly precipitated with organic solvent, then transferred to 
SPE and directly injected into the analytical instrument. Method is simple, fast and almost 
free from phospholipids [74]. This sample preparation approach has been successfully 
applied in metabolism studies of various drugs [75]. 
7.4. On-line SPE 
The on-line SPE offers speed, high sensitivity by the pre-concentrating factor, and low 
extraction cost per sample, but typically require the use of program switch valves and 
column re-configurations [71]. Biological samples can be directly injected into liquid 
chromatographic system without any sample preparations except for aliquoting samples, 
adding the internal standard and sometimes sample diluting and/or centrifugation. On-line 
SPE is considered as another dilute and injection approach like protein precipitation, 
however, it provides cleaner extract with reduced chance for matrix effect. Commonly used 
columns for on-line SPE are packed with large particles (typically > 20µm) of stationary 
material, such as polymeric and silica based, which work based on reversed phase, ion-
exchange or mixed mode of separation. The combination of large particle size in these 
narrow bore columns (typically 50x1 mm) and fast flow (typically 3-5 mL/min), called also 
as turbulent flow chromatography, promotes the rapid removal of proteins with 
simultaneous retention of the small-molecular analytes of interest. After flushing all the 
proteins to waste, the direction of the flow is switched; the analytes are back-flushed onto 
the analytical column for chromatographic separation and detection. Fully integrated home-
built or commercial systems enable eluting analytes from the extraction column onto 
analytical column in narrow bands. That allows multiple injections onto analytical column 
prior to elution into the instrument detector resulting in better sensitivity [76]. Most on-line 
SPE approaches use column-switching to couple with the analytical column as well as 
additional HPLC pump. Various instrument setups and column dimensions can be 
configured for the fast analysis of drugs and their metabolites in biological matrix at the 
ng/mL levels or lower [71].  
Typically, on-line SPE columns can withstand few hundred injections of diluted plasma or 
urine samples what depends on the injection volume and sample matrix [77]. Beside 
mentioned SPE sorbents for turbulent flow chromatography, restricted access materials 
(RAM), monolithic materials and disposable SPE cartridges are available. The working 
principle of RAM phases is to isolate macromolecules from the target small molecules in 
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biological samples based upon their particle sizes and also due the chromatographic 
interaction. The proteins, that are unable to penetrate into the hydrophobic pores and the 
hydrophilic outer layer of particles, are first eluted to waste, the smaller molecules 
penetrate into pores and are additionally retained through the hydrophobic forces [78]. 
RAM columns may be used either in single column mode, being extraction (SPE) and 
analytical column at same time, or extraction column in combination with second 
analytical column. Single column mode approach shows simplicity but is limited due to 
chromatographic separation power [79]. Monolith phases as extraction sorbents for 
sample treatment looks promising and has been reviewed recently [77]. Monolith columns 
may be very convenient as single column mode for high throughput method in LC-
MS/MS analysis [80]. 
8. Analytical methods for metabolite quantification 
LC-MS/MS has become the predominant bioanalysis method for pharmacokinetic and 
metabolism studies due to its inherent specificity, sensitivity and speed. A literature 
survey of analytical methods for metabolite determination in biological samples 
undoubtedly confirms that fact. However, HPLC coupled with other detector systems or 
other separation techniques is often used. As an example, analytical methods for 
determination of antidepressants and their metabolites [67] are shown. HPLC coupled to 
different detectors (73%), among them the most popular being mass spectrometry (35%) 
and UV detection (24%), is the most frequently used analytical method. Applications of 
electrophoretic and gas chromatography methods for analysis of antidepressants and 
their metabolites in biofluids have seldom been published in literature (13 and 9%, 
respectively). Since the data were collected in time frame 2000-2010 [67], the frequency of 
LC-MS/MS methods is believed to be growing and is nowadays significantly higher 
because mass spectrometers are lately more accessible. In this section the most frequently 
used separation techniques as well as detectors will be overviewed with emphasis on LC-
MS/MS. 
8.1. Liquid chromatography 
Good chromatographic separation is prerequisite for reliable and accurate quantification of 
metabolites in the biological samples. Baseline resolution must be achieved when liquid 
chromatography is coupled to non-MS detector. Although extensive chromatographic 
separation using LC-MS/MS is often not necessary, for certain cases, adequate resolution 
between drugs and various metabolites is required to avoid mass spectrometric 
interferences. Different metabolites may share the same MRM transition, such as 
hydroxylate metabolites [81] or glucuronides [37]. An example is shown in Figure 1. 
Additionally, unstable metabolites, such as N-oxides or glucuronides may be converted to 
parent drug by in-source dissociation or thermal degradation [79] or in collision cell (ion 
channel cross-talk). Interferences with endogenous compounds should also be avoided as 
matrix effect may appear (see 9.1.).  






Figure 1. LC-MS/MS chromatogram of urine sample from a patient receiving raloxifene. MRM 
transitions represent (A) raloxifene diglucuronide, (B) two raloxifene monoglucuronides (C) parent 
raloxifene, (D) haloperidol as internal standard. For analysis conditions refer to [37].  
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8.1.1. Reversed phase chromatography 
Reversed phase chromatography is most widely used technique in analysis of drugs and 
their metabolites due to its extensive application to most small molecules which are 
separated by their degree of hydrophobic interaction with the stationary phase. In most 
cases, metabolic changes lead to an increased polarity of the metabolite (strong shift for 
glucuronides and other phase II metabolites as also demonstrated in Figure 1) and therefore 
decreased retention on this stationary phase in relation to the parent drug [34]. The use of 
gradient elution is usually required to perform analysis of parent drug and polar 
metabolites. Common HPLC methods typically use a combination of water and either 
methanol or acetonitrile containing nonvolatile buffers, such as phosphate buffer and other 
inorganic additives as mobile phase. However, these nonvolatile additives cannot be 
recommended for LC-MS/MS because of possible MS contamination and also strong ion 
suppression effect. Volatile additives are used instead, such as formic or acetic acid (0.1% or 
lower) or ammonium acetate/formiate (2-10 mM) as salts. In order to maintain consistent 
chromatographic conditions, the pH of the mobile phase should be two units above or 
below pKa. C18 column is most commonly used. In some cases for polar metabolites short-
chain bonded phases, such as C8, phenyl or cyano are more appropriate. Another effective 
way to resolve the retention issue is to add ion-paring reagent into mobile phase. The 
formed neutral ion pars increase retention and also improve peak shape. Among different 
ion-paring reagents trifluoroacetic acid and other perfluorated acids for basic analytes and 
for instance nucleoside phosphates for acidic analytes are appropriate for LC-MS/MS 
analyses [79]. These additives, especially trifluoroacetic acid, should be used at low 
concentrations because they cause ion suppression. 
8.1.2. Hydrophilic interaction chromatography (HILIC)  
HILIC using low aqueous/high organic mobile phase is emerging as a valuable supplement 
to the reversed phase chromatography for the retention of polar analytes [82]. An 
appropriate amount of water (usually 5-15%) in the mobile phase is suggested for 
maintaining a stagnant enriched water layer on the surface of the polar stationary phase 
where the analytes partite. HILIC separates compounds by eluting with strong organic 
mobile phase against a hydrophilic stationary phase where elution is driven by increasing 
the water content in the mobile phase [83]. Although some column companies are marketing 
columns specific for HILIC, most columns used with normal phases, such as pure silica or 
cyano columns, can operate in HILIC conditions. The highly volatile organic mobile phases, 
such as methanol and acetonitrile provide low column backpressure and also increased 
ionization efficiency for MS detection. It has been reported that the ionization responses for 
basic and acidic polar compounds were enhanced by 5-8 fold in the positive ionization 
mode and up to 20-fold in the negative ionization mode by the HILIC LC-MS/MS methods 
as compared to the reversed phase LC-MS/MS method [84]. Low back-pressure allows 
higher flow rates and may be used for shortening run times, up to several times [85]. 
Another advantage of HILIC is the possibility to inject higher volumes of organic solvent 
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onto the column without impairing peak shapes. Therefore, evaporation and reconstitution 
step of organic extracts after extraction procedure could be omitted making improvement in 
sample preparation automation and throughput [86]. 
8.1.3. Chromatographic approaches for polar metabolites 
Metabolites, in particular glucuronides, have typically higher polarity than their parent 
drugs (Figures 1 and 2). This is the reason that classical reversed phase chromatography 
(e.g. C18) is sometimes not sufficient enough to maintain appropriate chromatographic 
retention of these analytes. In such cases already mentioned approaches like short-chain 
bonded reversed phases and ion-paring reagents (8.1.1.) or HILIC (8.1.2.) may be used. 
Additionally, mixed-mode columns with an embedded ion-paring group in the reversed 
phase stationary phase provide the capability for both ion-exchange and hydrophobic 
interactions in the mobile phase to retain ionizable polar analytes. The mixed-mode 
column allows retaining hydrophobic analytes by the reversed phase mechanism and 
hydrophilic analytes by the ion exchange mechanism at higher organic content in the 
mobile phase [87]. Normal phase chromatography may also be used for retention of 
polar analytes but due to limited amount of water allowed in the mobile phase, normal 
phase chromatography interfaced with MS requires complex pretreatment steps for 
biological samples and therefore has much fewer applications than reversed phase LC-
MS/MS [88]. 
The use of special packing material known as porous graphic carbon (PGC) is another 
alternative to achieve retention and separation of polar analytes. PGC chromatography 
commonly employs water, acetonitrile and methanol as the mobile phase but provides 
markedly greater retention and selectivity for polar analytes than reversed phase columns. 
For analyte elution PGC normally requires larger organic content in the mobile phase than 
reversed phase chromatography what consequently results in favorable sensitivity with MS 
detection [79, 83, 89].  
Derivatization of polar analytes results in the reduction of polarity and is therefore another 
possibility to enhance the chromatographic retention. But this approach is disadvantaged as 
it is not going toward high throughput, especially in case when the primary purpose of the 
derivatization is not the detection or stability improvement of the analyte. 
8.2. Strategies for high-throughput improvement in liquid chromatography 
Current trend in pharmaceutical analysis is the reduction of the analysis time and the 
increase in sample throughput without sacrificing the separation selectivity. High-
throughput bioanalytical assays are typically based on LC-MS/MS but may also be 
successfully extended to classical HPLC analyses. Approaches to achieve faster analyses 
include sample preparation (on-line automation or offline semi automation, section 7) and 
fast liquid chromatography. The later may be in general improved by three approaches: 
smaller particle size, shorter columns and higher mobile phase flow rates. 
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8.2.1. Ultra-high performance liquid chromatography (UHPLC) 
Reducing the particle diameter from 5.0 µm to 1.7 µm will, in principle, result in a 3-fold 
increase of efficiency, 1.7-fold increase in resolution, a 1.7-fold in sensitivity, and 3-fold 
increase in speed [79]. For fast analyses using sub-2µm particle column dimensions are 
typically 50x2 mm. An additional benefit of UHPLC is the low consumption of mobile 
phase, where it saves at least 80% compared to HPLC [90]. The high back-pressure resulting 
in decreased particle size need appropriately designed chromatographic system that would 
withstand such high pressure (instruments nowadays up to 1200 bars) and also provide at 
least possible extra column effects. To prevent clogging, manufacturers of UHPLC 
recommend filtration of both samples and solvents through 0.2 µm filter. Advantages as 
enhanced separation efficiency, short analysis time and high detection sensitivity make 
UHPLC coupled with MS/MS an even more powerful analytical support in pharmacokinetic 
studies [4]. 
8.2.2. Core-shell column  
An emerging alternative to porous particles are porous layer beads, known as core-shell or 
fused-core particles. The high separation efficiency of core-shell particles is a result of a 
faster analyte mass transfer from the mobile phase to outer porous layer of the particle. The 
improved dynamics of analyte movement through these columns result in higher effective 
peak capacities and separation efficiencies comparable to those fully porous sub-2µm but 
with advantage of lower back-pressure [91]. This technology is comparable to UHPLC in 
terms of chromatographic performance but demands neither expensive UHPLC 
instrumentation nor new laboratory protocols [88]. Commonly available columns, such as 
Ascentis, Poroshell and Kinetex, use different stationary phases and particle sizes (e.g. 
Kinetex 1.7 and 2.6 µm) and are widely used with classical HPLC instruments, also in our 
laboratories. Core-shell columns in combination with UHPLC-MS/MS exhibit excellent 
performance, as demonstrated in quantification of raloxifene and its three glucuronides [37].  
8.2.3. Monolithic chromatography 
The use of single rod monolith column is an alternative approach to the chromatographic 
columns packed with fine particles. The high permeability allows the use of higher flow 
rates and therefore shorter chromatographic runs, as demonstrated for the separation of 
bupropion metabolites in 23 seconds or for methylphenidate and its metabolite in 15 
seconds [71]. 
High flow rates may require flow splitting before entering MS. An attractive approach using 
monolith separation is to combine it with high flow on-line extraction, which allows fast 
extraction and separation of samples [77]. Current limitations in the application of these 
columns are the small pH range [2-8], poor temperature resistance, limited column 
dimensions and stationary phases (C8 and C18) as well as higher costs due to higher mobile 
phase consumption. 
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8.3. Other separation techniques 
Gas chromatography with mass spectrometry (GC-MS) is most useful for the analysis of 
trace amounts of organically extractable, non-polar, volatile compounds and highly volatile 
compounds that may undergo headspace analysis. The GC-MS analysis of polar 
compounds, such as metabolites, from biological matrices requires analyte extraction into a 
volatile organic solvent either directly or after chemical derivatization, which typically 
enhances the volatility of previously non-volatile organic compounds [25]. Most analytes 
need extensive time-consuming sample preparation including derivatization to become 
stable, volatile and amenable to the ionization technique. This drawback in throughput 
necessitated the direction of GC-MS to LC-MS. LC-MS has an advantage over GC-MS 
method in drug metabolism studies, particularly for low dosed and large drugs, and of 
course for the analysis of phase II metabolites. However, GC-MS may also have advantages, 
especially in clinical and forensic toxicology or doping control [54]. GC-MS has been 
frequently applied for quantification of glucuronides in biological samples but only after 
treatment with ß-glucuronidase in order to obtain parent drug before analysis [92]. The GC-
MS technique is receiving wider acceptance in various classes of antidepressant agents, 
representing 6% of overall analytical methods for determination of antidepressants and their 
metabolites [67]. 
Capillary electrophoresis (CE) is another separation method for quantification of 
metabolites. This method offers very high resolution capability, high efficiency and short 
time of analysis. Moreover, CE in many instances can have distinct advantages over HPLC 
in terms of simplicity, rapid method development, solvent saving and minimal sample 
requirement [10-30 nL injected) making this technique very interesting for rapid and 
practical analyses in the biomedical field. However, the main disadvantage is low 
sensitivity. For this reason, application of CE for analysis of antidepressants and their 
metabolites is not so widely reported [67]. Applicability of CE using UV-absorbance or mass 
spectrometry detection was reported for determination of tamoxifene and its phase I 
metabolites [68]. 
8.4. Mass spectrometry 
Currently, the QQQ using single or multiple reaction monitoring is most often used for 
quantitative analysis of small molecules in the pharmaceutical industry. QQQ or single 
stage MS, operating in SIM, is not anymore recommended for reliable bioanalytical 
quantification, because it suffers from insufficient selectivity in comparison with MRM. SIM 
can provide the selected ion at certain m/z value, but the matrix or impurity interferences 
may occur at the same m/z value. Beside lower selectivity, SIM shows also much lower 
sensitivity in comparison to MRM due to much higher background noise. However, in some 
specific cases of good chromatographic resolution and the absence of matrix interferences, 
SIM may be considered as an alternative quantification method. Occasionally, due to the 
nature of dissociation pathways, resulting in low molecular weight product ions, radial 
ejection preceding dissociation and/or charge stripping, reliable precursor → product ion 
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transitions cannot be established. Alternatively, a precursor → precursor scan for reducing 
noise can be employed [70].  
Also other analyzers, such as ion traps and TOF, have been widely and increasly used for 
metabolite quantification. Especially hybrid instruments which combine a QQQ (Q1 and 
colission cell) and ion trap or TOF (Qtrap, Q-TOF). These instruments can operate as true 
tandem mass spectrometry and are usually applied for this purposes. Q-TOF can also 
operate as TOF and thus provide accurate mass measurments. Additonaly, high resolution 
of TOF instruments allows the resolution of chromatographic peak from background 
interferences achieveing better sensitivity. However, it does apear that QQQ using MRM 
remain about three to five times more sensitive than TOF [93]. 
The selection of an appropriate ionization technique depends on the analyte characteristics, 
such as the structure, polarity or molecular weight. In LC-MS/MS analysis three atmospheric 
pressure ionization techniques cover the whole range of compound polarities and molecular 
weight: ESI, APCI and APPI. Moreover, the polarity mode can be chosen according to the 
acidic, neutral or basic properties of the analytes. If the right choice of ionization technique 
and the polarity mode is not so obvious, all available possibilities should be considered in 
order to obtain the best response for tested analytes. The softest ionization technique, ESI, is 
the method of choice for polar and ionic compounds. The advantage of soft ionization is in 
providing reliable information about molecular weight of the phase II metabolites in 
comparison to other ionization techniques [42]. For parent drug and phase I metabolites 
with a lower polarity, APCI and APPI may provide better ionization efficiency and 
sensitivity [34]. APPI has a similar application range as APCI, but slightly extended toward 
nonpolar compounds [32]. ESI is generally more susceptible to matrix ionization 
suppression than APCI [94]. In case of neutral steroids or other poorly ionizable analytes, 
derivatization can be employed in order to increase detection sensitivity, but additionally 
the chromatographic retention enhancement of such derivatizated analytes may therefore 
provide less matrix effect. On the other hand, the disadvantage of derivatization lies in an 
additional time consuming step for sample preparation [30]. The adjustment of the mobile 
phase for improving analyte response is much easier compared to derivatization. The effect 
of mobile phase on ESI efficiency is not well understood and hence the behavior of an 
analyte in different mobile phase conditions cannot be routinely predicted. Various factors 
can affect the ionization of analytes in ESI, such as pH, mobile phase additives, flow rate, 
solvent composition and concentration of electrolytes. It is recommended to evaluate the use 
of additives (e.g. formic acid, ammonium acetate) and organic modifiers in mobile phase to 
maximize the ionization efficiency of the analyte, which is highly dependent on its chemical 
structure. Acidic conditions often promote positive mode ionization of basic compounds 
and conditions, which are slightly below neutral, neutral or basic, promote negative 
ionization of acidic compounds.  
A dramatic difference in the ESI response can be found even when acetonitrile is replaced 
by methanol in mobile phase. It was reported that an analyte gave only weak ESI response 
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in the positive ionization mode in mobile phase containing acetonitrile with formic acid 
and/or ammonium acetate. But replacement of acetonitrile with methanol in mobile phase 
gave approximately 25-fold higher response. On the other hand, for the same analyte, 
mobile phases containing acetonitrile or methanol gave about the same response in negative 
ionization [79]. Another interesting example is analysis of bisphenol A and its metabolite in 
biological samples. In order to gain the highest possible sensitivity for bisphenol A and 
bisphenol A glucuronide, LC-MS/MS conditions were optimized. ESI ionization source 
operating in negative ionization mode was selected for further optimization of mobile 
phase. It was found that substitution of acetonitrile/water with methanol/water as mobile 
phase increased response of parent by approximately two-fold but at the same time 
decreased response of its metabolite by approximately three-fold. Acetonitrile was selected 
as organic modifier because metabolite quantification is the main concern of metabolism 
studies. Additionally, sufficiently high sensitivity is needed for metabolite determination as 
low concentrations are expected in such studies [4]. 
8.5. Other detection techniques 
UV, fluorescence or electrochemical detectors are usually coupled with liquid 
chromatograph for determination of drugs and their metabolites. Total analysis time of 
these methods is often long because baseline chromatographic separation is required for 
quantification purposes. In terms of reproducibility and robustness, UV and fluorescence 
detection have an advantage over mass spectrometry. However, methods are less sensitive 
and specific what requires extensive and time-consuming sample preparation compared to 
mass spectrometry. 
Before the advent of mass spectrometry, UV was the primary detection technique used in 
pharmacokinetics for quantification of drugs and their metabolites in biological matrices. 
Although robust, reliable, simple and easy to use, UV detection provides relatively poor 
sensitivity, especially when the compound of interest has no significant chromophore [44]. 
However, HPLC coupled with UV detection is still widely applicable for determination of 
drugs and their metabolites in biological samples [95-97]. 
In contrast to UV, fluorescence or electrochemical detection can be a very selective and 
sensitive detection technique. These detectors can extend the sensitivity by 1-3 orders of 
magnitude if the analyte exhibits, or can be readily derivatized to exhibit, fluorescence or 
electroactivity [7]. Some drugs such as morphine have good fluorophores which allows its 
detection without derivatization. For direct determination of morphine and its two 
glucuronides assays based on liquid chromatography with different detector systems (UV, 
fluorescence, electrochemical, MS) has been reported. Limits of quantifications for both 
metabolites were comparable for MS and fluorescence detection but were as expected higher 
for UV detection [98]. Oxidation vulnerability and native fluorescence properties of most 
biogenic amines may explain the long history of their quantification by these conventional 
HPLC detection methods. However, LC-MS/MS methods are rapidly emerging due to its 
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specificity, sensitivity and high throughput [99]. Electrochemical detection is also very 
suitable for determination of antioxidants, such as ascorbic acid or glutathione, in biological 
samples [100].   
When analytes do not exhibit fluorescence, electroactivity or have poor UV detection, 
derivatization can be performed to enhance their detection. In addition, chromatographic 
retention is enhanced by derivatization what is a very convenient in analysis of polar 
drug metabolites. Derivatization is an additional step in sample preparation where 
consideration regarding the stability of derivatizated analyte to solvolysis and thermal 
degradation need to be addressed. Nevertheless, fluorescence detection is still widely 
used [67, 68, 101].  
9. Aspects of analytical quality 
LC-MS/MS is currently considered as the method of choice for quantitative analysis of drugs 
and their metabolites. The advantages of using this technique in MRM mode due to high 
sensitivity, selectivity and speed allow developing high throughput methods with little or 
no sample preparation and minimal chromatographic retention. However, matrix effect may 
have a significant impact on such LC-MS/MS analyses [94, 102, 103]. Therefore, the 
evaluation of matrix effect as well as strategies for its elimination or minimization needs to 
be adequately addressed. Another important parameter for analytical quality is the selection 
of an appropriate internal standard for the compensation of possible loss of analytes during 
sample clean up and variations in instrument performance. Other LC-MS/MS issues, such as 
ion channel cross-talk and carry-over should also not be overlooked. Moreover, metabolite 
instability may have an influence on the analytical performance and will be additionally 
addressed here.  
9.1. Matrix effect 
Matrix effect (ME) is a term that describes any changes in the MS response of analyte that 
can lead to either a reduced response (ion suppression) or an increased response (ion 
enhancement) of the LC-MS system. ME is caused by molecules originating from the sample 
matrix or mobile phase that co-elute with the analyte of interest and therefore interfere with 
the ionization process in the MS ion source. Several approaches have been proposed to 
evaluate ME. Among them the post column infusion technique is widely used. Use of this 
qualitative evaluation technique allows the determination of the matrix effect of endogenous 
components in blank matrix. During analysis of blank matrix, analyte response is monitored 
to provide information where in the chromatographic run interferences between the analyte 
and matrix compounds occur. ME is illustrated as response deviation in the otherwise flat 
response time trace of the continuously post-column infused analyte [104]. This approach is 
very useful during method development because it provides information on the retention 
times where ME has to be expected, which can later be avoided for analyte of interest by 
optimizing chromatographic conditions.  
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For quantitative estimation of ME another well recognised approach is more suitable. 
Matuszewski et al. reported practical approach for the assessment of the absolute and 
relative ME as a part of validation of bioanalytical LC-MS/MS methods [94]. The difference 
in response between neat solution sample and post-extraction spiked sample is called the 
absolute ME, while difference between various lots of post-spiked samples is called the 
relative ME. As such will an absolute ME primary affect the accuracy and relative ME will 
affect the precision of the method. The determination of a relative ME is much more 
important than the determination of absolute ME in the evaluation and validation of 
bioanalytical method in biofluids [94]. The relative ME caused by interindividual variability 
in the sample matrix is assessed based on at least 5 lots of different matrices. Relative ME 
can be expressed as a coefficient of variation at particular concentration level or calculated 
based on slope lines. For the method to be considered reliable and free from the relative ME, 
the calculated coefficient of variation of determined slopes in different sources of matrices 
should not exceed 3-4% [105].  
ME is known to be both component and matrix dependent. It was demonstrated that 
matrix induced ion suppression is especially important for early eluting compounds, 
such as polar metabolites. Typically, ME more strongly influences lower than higher 
analyte concentrations [71]. The main source of the commonly observed ME of plasma 
samples is believed to be endogenous phospholipids and proteins. The 
lysophospholipids which normally elute earlier in reversed phase chromatography are 
more likely to cause matrix effects compared to the later eluting phospholipids in spite of 
the larger concentrations of the latter in plasma [106]. Phospholipids cause ion 
suppression in both, positive and negative ESI modes and must be removed or resolved 
chromatographically. 
To remove or reduce ME, modification to the sample extraction methodology (SPE or LLE 
instead of PP) and improved chromatographic separation must be performed. The majority 
of ME occur in the solvent front of a chromatographic run and if the analytes can be retained 
to some degree, matrix effects can be minimized. Suitable sample preparation and 
chromatographic conditions are linked together and form the basis of developing a 
successful and robust quantitative LC-MS/MS method [102, 103]. Another consideration 
when dealing with ME is selection of ionization interface. APCI is generally considered to be 
less prone to ion suppression compared with ESI [94, 105]. However, assay sensitivity and 
thermal stability of the analyte should be evaluated for eventual APCI application. Reducing 
the flow rate [20 µl/min or below) directed to ESI source by post column splitting may also 
reduce or completely remove the ion suppression [107]. Additionally to other approaches 
UHPLC technology in combination with polymeric mixed-mode SPE and appropriate 
mobile phase pH may provide significant advantages for reducing ME [73]. Mobile phase 
additives such as triethylamine and trifluoroacetic acid can also lead to ion suppression. The 
use of other reagents such as formic or acetic acid, trifluoroacetic acid in conjunction with 10 
mM ammonium acetate or addition of 1% propionic acid to the mobile phase may overcome 
the ME of trifluoroacetic acid. Triethylamine may be replaced with other ion paring reagent 
such as hexylamine [70].  
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However, the most efficient way to eliminate the influence of ME on the accuracy and 
precision of a quantitative analytical method is the use of stable isotope labeled analogs as 
internal standards [105]. 
9.2. Selection of internal standard 
The selection of a suitable internal standard (IS) is one of the key parameters for establishing 
a successful LC-MS/MS method. Usually, stable isotope, such as 2H (D, deuterium), 13C, 15N 
or 17O, labeled standards are most appropriate for compensation of possible loss of analytes 
during sample clean up and variations in instrument performance (typically caused by 
matrix effect) since their physicochemical characteristics are practically identical to that of 
unlabeled analyte. In general, a stable isotope labeled IS is considered to be ideal, since it 
shows almost same behavior to the analyte of interest in sample preparation, 
chromatography as well as in ionization process [102]. However, issues like isotopic purity 
of IS, cross-contamination and cross-talk between MS ion channels, as well as IS stability 
and isotopic integrity of the label in biological fluid and during sample preparation should 
be carefully addressed [94].  
Mass difference between analyte and IS should be at least 3 Da to avoid signal 
contribution of the natural isotopes to the signal of IS. Although deuterated IS are most 
frequently used, several disadvantages need to be considered in some cases, such as 
different extraction recoveries and retention times between such IS and analyte or 
exchange of deuterium atoms by hydrogen atoms [108]. For example, differences in 
retention times for deuterium labeled (d16) and unlabeled bisphenol A compounds is 
shown in Figure 2, where both, labeled metabolite and parent compound eluted slightly 
before their unlabeled analogs. Interestingly to mention, deuterium labeled bisphenol A 
(d16) has all 16 hydrogen atoms substituted by deuterium atoms but is actually d14 labeled 
(mass shift 14 Da in MRM transition, Figure 2) because two deuterium atoms from the 
functional group (–OD) are easily exchangeable by hydrogen atoms. The observable 
chromatographic retention time shifts for deuterated analogs depend on the number of 
deuterated atoms in structure. Deuterated analogs have no retention time shifts up to 
approximately six deuterium atoms [34] but when more deuterium atoms are included in 
structure, such as ten, the retention time shift may be significant (up to 1.2 min) [108]. 
Therefore, other stable isotope labeled IS, such as 13C, are considered as more appropriate 
[108].  
The concentration of IS used for sample preparation is also important and should be 
approximately at the middle of calibration curve. Optimization of IS concentration is 
critical to avoid ion suppression by co-eluting analyte leading to standard curve non-
linearity [70]. Even if stable labeled isotope IS is used, ME should still be investigated. 
Namely if ion suppression significantly reduces the signal of both, analyte and IS, the 
signal to noise ratio may decrease to a point where accuracy and precision may be 
negatively affected [102]. 
 Chromatography – The Most Versatile Method of Chemical Analysis 114 
Problems may occur when more than one compound is determined in the same analytical 
method. A number of labeled IS identical to number of analyzed compounds would in this 
case be required [102]. This is not always practically feasible, especially not for stable isotope 
labeled drug metabolites as their availability is very limited. In such cases, to assure the 
suitability of the quantification method for determination of drugs and their metabolites, 
ME evaluation should be carefully addressed [37]. On the other hand, example for 
simultaneous determination of parent compound and its metabolite using both labeled IS [4] 
is shown in Figure 2. It is preferred that the labeled IS product ion used for the MRM 
transition retains the stable isotope moiety as for m/z 403 → 227 (bisphenol A-glucuronide) 
versus 417 → 241 (deuterated bisphenol A-glucuronide) in Figure 2.  
However, labeled ISs are not always available or can be very expensive. As an alternative, 
structural analogues can be used, with consideration of the structural similarities between 
the IS and the analyte. To be suitable, the ionization of the analogue must be compared with 
analyte and should preferably co-elute with the analyte (Figure 1). The selected analog IS 
should not correspond to any metabolic product of analyte, such as hydroxylated or N-
dealkylated metabolites [108]. Nevertheless, in many cases analog ISs or structurally 
unrelated ISs are not able to compensate the ME [94, 105]. In such situation, other more 
rigorous approaches to reduce or eliminate ME should be applied (see 9.1.).   
9.3. LC-MS pitfalls 
Metabolite may produce a molecular ion that is identical to parent ion through in source 
conversion. Typical metabolites for such conversion are glucuronides, sulfates or N-oxides 
[79]. N-oxide conversion may also serve for identification purposes as this transformation 
takes place in APCI source and represent another potential way to differentiate N-oxide 
from hydroxylated metabolites (both with exact mass) since the later usually do not undergo 
thermal deoxygenation [23]. Therefore, an inadequate chromatographic separation between 
parent drug and such metabolites will result in over estimation of parent drug concentration 
in the presence of these isomeric compounds. The same situation may happen also by ion 
channel cross-talk in MRM mode, which means that fragment issued from the other scanned 
transition is still present in collision cell. Metabolites, such as diverse glucuronides, that give 
the same product ion as parent drug, have to be therefore chromatographically separated. 
However, for co-eluting compounds, such as analytes and their IS, the absence of cross-talk 
has to be demonstrated [37].  
Carry-over, which is the appearance of an analyte signal in a blank injection subsequently to 
analysis of high concentration samples, is also a common problem in LC-MS/MS methods. 
This problem occurs due to retention of analytes by adsorption on active surfaces of the 
autosamples, solvent lines, extraction columns (e.g. online SPE) or the analytical column. 
Most carry-over problems can be minimized by an appropriate choice of injector wash 
solutions and methods, by proper choice of mobile phase and tubings, and by choice of 
suitable stationary phase and proper variation in the solvent strength [70]. Carry-over 
becomes prominent after injection of analyte at high concentration and should be assessed 
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during the validation of the method. Carry-over is usually expressed as percentage of 
detected analyte in blank sample regarding to its limit of quantification [4] and may 







Figure 2. LC-MS/MS chromatogram in MRM mode for metabolite (BPAG) and parent bisphenol A 
(BPA) of a typical microsomal incubation. (A) mass transition for BPAGd16 (internal standard for BPAG), 
(B) mass transition for BPAG, (C) mass transition for BPAd16 (internal standard for BPA), (D) mass 
transition for BPA. For analysis conditions refer to [4]. 
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9.4. Metabolite stability 
For drugs and metabolites that are unstable, with one converting to other, conditions used 
during sample preparation and analysis must be optimized in order to minimize such 
conversion and to achieve accurate quantification of the drug and metabolite. Common 
factors that affect drug and drug metabolite stability in biological matrices include 
temperature, light, pH, oxidation and enzymatic degradation [110]. Acyl glucuronides (O-
ester conjugates) are probably the most commonly encountered problematic metabolites 
in bioanalysis. Acyl glucuronides are unstable and hydrolyze to release aglycone under 
neutral and alkaline conditions. Different acyl glucuronides have been shown to have 
different rates of hydrolysis. However, mildly acidic conditions (pH 3-5) should be the 
most desirable pH for minimizing the reaction in biological samples [59, 111]. Acyl 
glucuronides (1-O-acyl glucuronides) are also susceptible to internal migration under 
both, physiological and alkaline conditions. The rate of migration resulting in 2-, 3- and 4-
O-acyl glucuronides increases with increasing pH and temperature. Such isomeric 
glucuronides are not susceptible to hydrolysis by ß-glucuronidases and may compromise 
the quantification of metabolites and total parent drug when indirect quantification 
approach via conjugate cleavage is applied [111]. Similar to O-glucuronides, N-
glucuronides can be converted back to parent drug under acidic/basic/neutral pH 
conditions or at elevated sample processing temperature, but this instability is largely 
compound dependent. For example olanzapine glucuronide can be readily cleaved under 
acidic conditions, clozapine and cyclizine glucuronides are unstable at range pH 1-3 and 
doxepin glucuronide at pH 11 [112]. Lactone is another commonly unstable metabolite 
function group which may be converted to its open ring hydroxy acid drug. Lactone 
metabolites, such as atorvastatin metabolite, require optimization of the sample pH 
(typically 3-5) in order to minimize the hydrolysis of lactone metabolite back to parent 
drug [113]. 
N-oxides are also unstable in solutions and biological samples during sample preparation, 
especially under strong acidic or basic conditions. Light exposure may further accelerate the 
decomposition of these metabolites. Other compounds are also susceptible to 
photodegradation such as, catechols, nisoldipine, rifampin and their metabolites and should 
be protected from light during sample preparation and analysis [112]. 
10. Conclusion 
Current drug discovery efforts have been focused on identification of drug metabolism 
and pharmacokinetic issues at the earliest possible stage in order to reduce the attrition 
rate of drug candidates during the developmental phase. Metabolic fate of drugs can be 
responsible for problems associated with their bioavailability, interindividual variability, 
drug-drug interactions, pharmacologic activity or the toxicity. Different in vitro methods, 
from subcelullar to organ range, and in vivo studies are applied for the clarification of 
drug metabolism. Among them microsomes and hepatocytes are the most frequently 
utilized in vitro models in drug metabolic profiling and drug interaction studies. For the 
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successful monitoring of the drug metabolism, suitable bioanalytical methods have to be 
developed and validated. Liquid chromatography coupled with mass spectrometry has 
become the most powerful analytical tool for identification and quantification of drug 
metabolites.  
The known identity of metabolites is the prerequisite for a suitable metabolic assessment of 
drugs. Appropriate LC-MS instrumentation is clearly critical to both, detection and 
structural elucidation. Tandem mass spectrometry instruments are beside their key role for 
metabolite quantification also well suited for qualitative purposes as they enable different 
scan possibilities (constant neutral loss, precursor ion, product ion) for structural 
characterization of metabolites. However, the drive to more versatile and powerful 
instruments which can perform intelligent data dependent experiments and accurate mass 
measurements has led to newer high resolution mass analyzers, such as Q-TOF instruments, 
which now dominate the metabolite identification field. 
Direct quantification of metabolites in biological samples is the most appropriate approach, 
but also others approaches such as indirect quantification through parent drug after 
metabolite hydrolysis or quantification supported by using response factors may be used 
which primary depends on the availability of suitable authentic standards. Analytical 
methods for metabolite quantification are based on liquid chromatography or other 
separation techniques coupled with various detector systems where LC-MS/MS plays 
predominant role in bioassays for pharmacokinetic and metabolism studies due to its 
inherent specificity, sensitivity and speed.  
In order to support metabolism experiments in a timely manner, the use of high 
throughput methods for the analysis of drugs and their metabolites in biological samples 
has become an essential part, especially in the most time consuming sample preparation. 
Trend is going toward semi automated off-line sample treatment in 96-well plate format 
or on-line SPE after direct injection of samples. Additionally, other high throughput 
approaches can be introduced. Ultra-high performance liquid chromatography with small 
particles and monolithic chromatography offer improvements in speed, resolution and 
sensitivity compared to conventional chromatographic techniques. Hydrophilic 
interaction chromatography (HILIC) or other specialized columns suitable for polar 
metabolites are emerging as a valuable supplement to classical reversed phase 
chromatography. 
The main advantage of LC-MS/MS allows development of high throughput methods with 
little or no sample preparation and minimal chromatographic retention. However, matrix 
effect may have a significant impact on such analyses. Matrix effect issue is frequently 
underestimated and should be adequately addressed. Not without reason, matrix effect 
have been called the Achilles heel of quantitative LC-ESI-MS/MS [103]. The use of stable 
isotope labeled analog as internal standard is the most efficient way to reduce matrix 
effect. But normally, additional approaches to reduce or eliminate matrix effect are 
needed. 
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